

Supplementary Appendix

Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study across sixteen countries

Content

Table S1 Contributing hospitals.....	3 – 6
Figure S1 Selection of study population.....	7
Table S2 Baseline characteristics stratified by data source and age	8 – 9
Table S3 Detailed specification of pre-existing cardiac disease in CAPACITY.....	10 – 11
Figure S2 Complaints at presentation stratified by age.....	12
Figure S3 Complaints at presentation stratified by age and prior history of cardiac disease.....	13
Table S4 Complaints, vitals and laboratory values at admission stratified by data source and age.....	14 – 15
Table S5 Baseline characteristics stratified by admission to a critical care unit.....	16
Table S6 Complaints, vitals and laboratory values at admission stratified by admission to a critical care unit.....	17 – 18
Table S7 Baseline characteristics stratified by mortality.....	19
Table S8 Complaints, vitals and laboratory values at admission stratified by mortality.....	20 – 21
Table S9 Outcome at discharge stratified by data source and age.....	22
Table S10 Outcome at discharge stratified by admission to a critical care unit.....	23
Table S11 Outcome at discharge stratified by mortality.....	24
Table S12 Subgroup analyses.....	25
Table S13 Sensitivity analyses.....	26
Table S14 Associations across data sources.....	27

Table S1: Contributing hospitals**CAPACITY-COVID**

Country	Site name
Belgium	Antwerp University Hospital
	AZ Maria Middelares
	CHU UCL Namur – Site Godinne
	Jessa Hospital
	University Hospital Brussels
Egypt	One Day Surgery Hospital
France	SSR Val Rosay
Iran	Tehran Heart Center
Israel	EMMS Hospital
Italy	San Luigi Gonzaga University Hospital
Netherlands	Admiraal de Ruyter Hospital
	Albert Schweitzer Hospital
	Amphia Hospital
	Amstelland Hospital
	Amsterdam University Medical Center
	Antonius Hospital
	Beatrix Hospital
	Bernhoven Hospital
	Bravis Hospital
	Catharina Hospital
	Deventer Hospital
	Diakonessenhuis
	Dijklander Hospital
	Elizabeth-TweeSteden Hospital
	Erasmus University Medical Center
	Franciscus Gasthuis
	Franciscus Vlietland
	Gelre Hospitals, location Apeldoorn
	Gelre Hospitals, location Zutphen
	Groene Hart Hospital
	Haaglanden Medical Center
	Hospital Group Twente
	Ikazia Hospital
	Isala
	Jeroen Bosch Hospital
	LangeLand Hospital
	Leiden University Medical Center
	Maasstad Hospital
	Martini Hospital
	Meander Medical Center
	Medical Center Leeuwarden
	Medisch Spectrum Twente
	Rijnstate Hospital
	Rode Kruis Hospital
	Saxenburg Medical Center
	Slingeland Hospital
	Spaarde Gasthuis
	St. Antonius Hospital
	St. Jansdal
	Treant Zorggroep
	University Medical Center Utrecht
	van Weel-Bethesda Hospital
	Zaans Medical Center

	Zuyderland Medical Center
Portugal	Hospital do Espirito Santo
	Hospital Prof. Doutor Fernando Fonesca
Russia	I.M. Sechenov First Moscow State Medical University
Saudi Arabia	King Fahd Hospital of the University
Spain	INCLIVA Research Institute, University of Valencia
	University Hospital Complex of Granada
Switzerland	University Hospital of Geneva
United Kingdom	Barts Health NHS Trust
	Leeds Teaching Hospitals NHS Trust
	Northumbria Healthcare NHS Foundation Trust
	Royal Devon and Exeter NHS Foundation Trust
	Royal Free London NHS Foundation Trust
	Salford Royal NHS Foundation Trust
	Southern Health and Social Care Trust
	The Newcastle upon Tyne Hospitals NHS Foundation Trust
	University College London Hospitals NHS Foundation Trust
	University Hospitals Bristol NHS Foundation Trust
	University Hospitals of Leicester NHS Trust
LEOSS	
Country	Site name
Belgium	National MS Center Melsbroek
Germany	Agaplesion Diaconia Hospital Rotenburg
	ARCIM Institute an der Filderklinik
	Bethesda Hospital Bergedorf
	Braunschweig Hospital
	Bundeswehr Hospital Koblenz
	Cardiology and Intensive Care Medicine
	Carl-Thiem-Hospital Cottbus
	Charité Berlin
	Clinic Munich
	Elbland Hospital Riesa
	Evangelical Hospital Herne
	Evangelisches Stadtkrankenhaus Saarbrücken
	German Heart Center Munich
	Hegau-Bodensee-Clinic Singen
	Helios-Hospital Pir
	Hospital Bremen-Center
	Hospital Dortmund
	Hospital Ernst von Bergmann
	Hospital Fulda
	Hospital Ingolstadt
	Hospital Leverkusen
	Hospital Nuremberg North
	Hospital of the Augustinian Cologne
	Hospital Oldenburg
	Hospital Osbrück
	Hospital Passau
	Hospital Saar Sulzbach
	Hospital South-Eastern Bavaria AG – Trostberg
	Hospital St. Joseph-Stift Dresden
	Hospital Stuttgart
	Hospital Traunstein
	Hospital Trier
	Hospital zum Heiligen Geist, Kempen
	Hospitals of the City of Cologne GmbH

Johannes Wesling Hospital Minden
Justus-Liebig-University Giessen
Kreuzcher Diakonia
Malteser Hospital St. Hildegardis Cologne
Malteser Hospital St. Franziskus-Hospital Flensburg
Marien Hospital Herne, University Hospital Bochum
Medical School Hannover
Municipal Hospital Karlsruhe
Nephrological Center Villingen-Schwenningen
Oberlausitz-Hospital
Oncological practice Rundestrassse Hannover
Otto-von-Guericke-University Magdeburg
Petrus Hospital Wuppertal
Practice Dr. Boebel
Practice for general medicine Drs. Elisabeth Schrödter & Gabriele Müller-Jörger
Practice Gotenring
Preetz Hospital
RkK Hospital Freiburg
Robert Koch Institute
Robert-Bosch-Hospital Stuttgart
SHG Clinics Völklingen, Lung Center Saar
Sophien Hospital GmbH Hannover
Sophien- and Hufeland Clinic Weimar
Srh Wald-Hospital Gera
St. Vincenz Hospital Datteln
St. Vincenz Hospital Limburg/Lahn
St. Josef Hospital Kupferdreh
St. Josef-Hospital - Catholic Hospital Bochum
St. Josefs-Hospital Wiesbaden
Stankt Vincenz Hospital Menden
Technical University of Munich, University Hospital rechts der Isar, Munich, Germany
Thorax-Hospital Heidelberg
Tropical Clinic Paul-Lechler Hospital Tübingen
University Heart Center Freiburg Bad Krozingen
University Hospital Augsburg
University Hospital Bonn
University Hospital Cologne
University Hospital Dresden
University Hospital Düsseldorf
University Hospital Erlangen
University Hospital Essen
University Hospital Frankfurt
University Hospital Freiburg
University Hospital Göttingen
University Hospital Halle
University Hospital Hamburg-Eppendorf
University Hospital Heidelberg
University Hospital Jena
University Hospital Munich/ LMU
University Hospital Münster
University Hospital Regensburg
University Hospital Rostock
University Hospital RWTH Aachen
University Hospital Saarland
University Hospital Schleswig-Holstein – Kiel

	University Hospital Schleswig-Holstein – Lübeck
	University Hospital Tübingen
	University Hospital Ulm
	University Hospital Würzburg
	University Medicine of the Johannes Gutenberg University Mainz
	Zeisigwald Hospitals Bethanien Chemnitz
Italy	S. Andrea Hospital University of Rome
Latvia	Pauls Stradiņš Clinical University Hospital
Spain	Complejo Hospitalario de Navarra
	Hospital University Aru de Vilanova
	University Hospital Joseo Trueta
Switzerland	Ente Ospedaliero Cantole
	Kantonsspital St. Gallen
	Luzerner Kantonsspital
	University Hospital Basel
	University Hospital of Bern
Turkey	Hacettepe University
	Pamukkale University, School of Medicine
	University of Health Sciences Istanbul




Figure S1: Selection of study population

Table S2: Baseline characteristics stratified by data source and age

	Overall	CAPACITY-COVID		LEOSS	
		≤65 years	>65 years	≤65 years	>65 years
Total	10481	3081	3699	1934	1767
Age, years (%)					
Median, [IQR]	NA	55 [47 – 60]	76 [72 – 82]	NA	NA
18 – 25	148 (1.4)	67 (2.2)	0 (0.0)	81 (4.2)	0 (0.0)
26 – 35	429 (4.1)	204 (6.6)	0 (0.0)	225 (11.6)	0 (0.0)
36 – 45	717 (6.8)	395 (12.8)	0 (0.0)	322 (16.6)	0 (0.0)
46 – 55	1503 (14.3)	943 (30.6)	0 (0.0)	560 (29.0)	0 (0.0)
56 – 65	2218 (21.2)	1472 (47.8)	0 (0.0)	746 (38.6)	0 (0.0)
66 – 75	2346 (22.4)	0 (0.0)	1699 (45.9)	0 (0.0)	647 (36.6)
76 – 85	2247 (21.4)	0 (0.0)	1423 (38.5)	0 (0.0)	824 (46.6)
>85	873 (8.3)	0 (0.0)	577 (15.6)	0 (0.0)	296 (16.8)
Sex, female (%)	4051 (38.7)	1098 (35.6)	1438 (38.9)	747 (38.6)	768 (43.5)
Ethnicity					
Arab	NA	317 (11.9)	141 (4.2)	NA	NA
Asian	518 (5.7)	304 (11.4)	111 (3.3)	86 (5.5)	17 (1.1)
Black	278 (3.0)	169 (6.3)	65 (1.9)	40 (2.5)	4 (0.3)
Latin-American	25 (0.3)	14 (0.5)	7 (0.2)	4 (0.3)	0 (0.0)
White	7606 (83.1)	1686 (63.1)	2954 (87.8)	1444 (91.7)	1522 (98.6)
Other	NA	181 (6.8)	88 (2.6)	NA	NA
BMI (kg/m²) (%)					
Mean, (+/- SD)	NA	29.1 (5.9)	27.3 (5.3)	NA	NA
Underweight (<18.5)	125 (1.8)	11 (0.5)	64 (2.4)	21 (1.7)	29 (2.7)
Normal weight (18.5 – 24.9)	2095 (30.1)	474 (23.4)	859 (32.6)	361 (29.4)	401 (37.2)
Overweight (25.0 – 29.9)	2691 (38.6)	805 (39.7)	1035 (39.3)	455 (37.1)	396 (36.7)
Obese (30.0 – 34.9)	1372 (19.7)	468 (23.1)	480 (18.2)	248 (20.2)	176 (16.3)
Morbidly obese (> 34.9)	685 (9.8)	270 (13.3)	196 (7.4)	143 (11.6)	76 (7.1)
Cardiovascular risk factors (%)					
Diabetes	2482 (24.0)	633 (20.8)	1107 (30.2)	239 (12.6)	503 (29.2)
Hypertension	4973 (48.4)	954 (31.6)	2187 (60.4)	595 (31.3)	1237 (71.5)
Peripheral arterial disease	442 (5.1)	41 (1.7)	238 (8.7)	28 (1.5)	135 (8.1)
Cardiac disease (%)					
Any history of cardiac disease	3195 (30.5)	415 (13.5)	1755 (47.4)	184 (9.5)	841 (47.6)
Arrhythmia/conduction disorder	1557 (14.9)	115 (3.7)	872 (23.6)	60 (3.1)	510 (28.9)
Atrial fibrillation/flutter	1238 (11.9)	57 (1.9)	661 (17.9)	54 (2.9)	466 (27.0)
Coronary artery disease	1589 (15.2)	221 (7.2)	793 (21.5)	115 (5.9)	460 (26.1)
Myocardial infarction	497 (4.8)	56 (1.8)	208 (5.7)	50 (2.6)	183 (10.8)
Heart failure	762 (7.4)	49 (1.6)	377 (10.2)	46 (2.4)	290 (17.2)
NYHA I/II	182 (1.8)	12 (0.4)	100 (2.8)	8 (0.4)	62 (3.9)
NYHA III/IV	129 (1.3)	2 (0.1)	47 (1.3)	10 (0.5)	70 (4.4)
Valvular heart disease	402 (3.9)	37 (1.2)	273 (7.4)	14 (0.7)	78 (4.6)
Comorbidities (%)					
Chronic kidney disease	1274 (12.3)	129 (4.2)	617 (16.8)	107 (5.6)	421 (24.5)
COPD	994 (9.6)	176 (5.8)	578 (15.8)	56 (3.0)	184 (10.7)
Use cardiovascular drugs (%)					
ACE-inhibitors	1848 (18.1)	348 (11.3)	783 (21.2)	205 (11.4)	512 (30.9)
Aldosterone antagonist	390 (3.8)	38 (1.2)	183 (5.0)	39 (2.1)	130 (7.7)
Anti-platelet	2003 (19.4)	330 (10.7)	1031 (27.9)	138 (7.4)	504 (29.8)
Angiotensin receptor blocker	1340 (13.1)	216 (7.0)	538 (14.6)	186 (10.4)	400 (24.5)
Calcium-blocker	1658 (16.0)	338 (11.0)	757 (20.5)	183 (9.8)	380 (22.5)
Diuretic	2032 (19.7)	291 (9.5)	1007 (27.3)	157 (8.4)	577 (34.3)
Insulin	699 (6.7)	195 (6.3)	310 (8.4)	51 (2.7)	143 (8.3)
Lipid-lowering	2978 (30.2)	629 (20.4)	1613 (43.7)	184 (11.5)	552 (37.1)

Oral anti-diabetic	1258 (12.0)	354 (11.5)	659 (17.8)	91 (4.7)	154 (8.7)
--------------------	-------------	------------	------------	----------	-----------

ACE = Angiotensin Converting Enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; IQR = Interquartile Range; NYHA = New York Heart Association; SD = Standard Deviation

Table S3: Detailed specification of pre-existing cardiac disease in CAPACITY COVID

	Overall	≤65 years	>65 years
Total	6780	3081	3699
Arrhythmia/conduction disorder			
Any	987 (14.6)	115 (3.7)	872 (23.6)
Supraventricular tachycardia	781 (11.5)	83 (2.7)	698 (18.9)
Atrial fibrillation	676 (10.0)	51 (1.7)	625 (16.9)
Atrial flutter	62 (0.9)	6 (0.2)	56 (1.5)
Atrial tachycardia	17 (0.3)	5 (0.2)	12 (0.3)
AVNRT	21 (0.3)	10 (0.3)	11 (0.3)
AVRT	2 (0.0)	1 (0.0)	1 (0.0)
Unspecified	35 (0.5)	11 (0.4)	24 (0.6)
Ventricular tachycardia (VT)	55 (0.8)	14 (0.5)	41 (1.1)
Non-sustained VT	21 (0.3)	6 (0.2)	15 (0.4)
Sustained VT	14 (0.2)	3 (0.1)	11 (0.3)
Ventricular fibrillation	21 (0.3)	6 (0.2)	15 (0.4)
Conduction disorder	127 (1.9)	11 (0.4)	116 (3.1)
First-degree AV-block	26 (0.4)	2 (0.1)	24 (0.6)
Second-degree AV-block	13 (0.2)	1 (0.0)	12 (0.3)
Third-degree AV-block	28 (0.4)	1 (0.0)	27 (0.7)
Left bundle branch block	26 (0.4)	5 (0.2)	21 (0.6)
Right bundle branch block	28 (0.4)	0 (0.0)	28 (0.8)
Long-QT	6 (0.1)	1 (0.0)	5 (0.1)
Unspecified	7 (0.1)	2 (0.1)	5 (0.1)
Sinus node dysfunction	39 (0.6)	4 (0.1)	35 (0.9)
Congenital heart disease	30 (0.4)	13 (0.4)	17 (0.5)
Coronary artery disease	1014 (15.0)	221 (7.2)	793 (21.5)
Stable angina	296 (4.4)	61 (2.0)	235 (6.5)
Unstable angina	157 (2.3)	36 (1.2)	121 (3.3)
NSTEMI	264 (4.0)	56 (1.8)	208 (5.7)
STEMI	279 (4.2)	58 (1.9)	221 (6.1)
Intervention coronary artery disease			
PCI	493 (7.3)	112 (3.6)	381 (10.4)
CABG	277 (4.1)	47 (1.5)	230 (6.3)
Heart failure	426 (6.3)	49 (1.6)	377 (10.2)
NYHA I/II	112 (1.7)	12 (0.4)	100 (2.9)
NYHA III/IV	49 (0.8)	2 (0.1)	47 (1.4)
Cardiomyopathy			
Arrhythmogenic	25 (0.4)	1 (0.0)	24 (0.7)
Dilated	79 (1.2)	9 (0.3)	70 (1.9)
Hypertensive	41 (0.6)	6 (0.2)	35 (1.0)
Hypertrophic	19 (0.3)	3 (0.1)	16 (0.4)
Ischemic	85 (1.3)	11 (0.4)	74 (2.0)
Myocarditis	2 (0.0)	1 (0.0)	1 (0.0)
Non-compaction	4 (0.1)	0 (0.0)	4 (0.1)
Restrictive	2 (0.0)	0 (0.0)	2 (0.1)
Toxic	3 (0.0)	1 (0.0)	2 (0.1)
Valvular	43 (0.6)	3 (0.1)	40 (1.1)
Unspecified	31 (0.5)	4 (0.1)	27 (0.7)
Valvular heart disease	310 (4.6)	37 (1.2)	273 (7.4)
Aortic stenosis	168 (2.5)	16 (0.5)	152 (4.1)
Aortic regurgitation	46 (0.7)	9 (0.3)	37 (1.0)
Mitral stenosis	18 (0.3)	2 (0.1)	16 (0.4)
Mitral regurgitation	95 (1.4)	11 (0.4)	84 (2.3)
Pulmonary regurgitation	2 (0.0)	1 (0.0)	1 (0.0)
Tricuspid regurgitation	44 (0.6)	1 (0.0)	43 (1.2)

Interventions valvular heart disease			
Intervention performed	130 (1.9)	17 (0.6)	113 (3.1)
Intervention planned	6 (0.1)	0 (0.0)	6 (0.2)

AVNRT = AV-nodal Reentrant Tachycardia; AVRT = Atrioventricular Reentrant Tachycardia; AV = Atrioventricular; CABG = Coronary Artery Bypass Surgery; NSTEMI = Non-ST-Elevation Myocardial Infarction; NYHA = New York Heart Association; PCI = Percutaneous Coronary Intervention; STEMI = ST-Elevation Myocardial Infarction; VT = Ventricular Tachycardia




Figure S2: Complaints at presentation stratified by age.




Figure S3: Complaints at presentation stratified by age and prior history of cardiac disease. Red = patients with pre-existing cardiac disease, blue = patients without pre-existing cardiac disease.

Table S4: Complaints, vitals and laboratory values at admission stratified by data source and age

	Overall	CAPACITY-COVID		LEOSS	
		≤65 years	>65 years	≤65 years	>65 years
Total	10481	3081	3699	1934	1767
Admission					
Onset of symptoms to admission, days, median, [IQR]	6 [2 – 9]	7 [3 – 10]	6 [2 – 9]	5 [1 – 8]	3 [0 – 7]
Complaints at admission (%)					
Anosmia	402 (4.1)	182 (6.5)	89 (2.6)	109 (6.0)	22 (1.3)
Chest pain	NA	350 (12.5)	215 (6.3)	NA	NA
Cough	5472 (56.4)	1965 (70.1)	2051 (60.1)	874 (48.1)	582 (35.0)
Dyspnea	5056 (52.6)	1910 (68.1)	2107 (61.8)	555 (31.2)	484 (30.0)
Fatigue	2777 (28.6)	984 (35.1)	1175 (34.4)	288 (15.8)	330 (19.8)
Fever	5852 (60.3)	2129 (75.9)	2251 (66.0)	847 (46.6)	625 (37.6)
Gastrointestinal symptoms	2055 (21.2)	795 (28.3)	913 (26.8)	203 (11.2)	144 (8.7)
(Pre) syncope	NA	98 (3.5)	188 (5.5)	NA	NA
Orthopnea	NA	55 (2.0)	56 (1.6)	NA	NA
Palpitations	117 (1.2)	28 (1.0)	52 (1.5)	18 (1.0)	19 (1.1)
Peripheral edema	NA	12 (0.4)	36 (1.1)	NA	NA
Sore throat	776 (8.0)	314 (11.2)	243 (7.1)	165 (9.1)	54 (3.2)
Vitals at admission (%)					
Temperature (°C)					
Mean, (SD)	NA	37.8 (1.0)	37.6 (1.1)	NA	NA
< 35.1	49 (0.6)	13 (0.5)	29 (0.9)	1 (0.1)	6 (0.8)
35.1 – 37.2	2821 (37.4)	932 (34.2)	1249 (38.5)	303 (38.7)	337 (43.0)
37.3 – 37.9	1698 (22.5)	622 (22.8)	731 (22.5)	177 (22.6)	168 (21.5)
38.0 – 38.9	2030 (26.9)	759 (27.8)	868 (26.7)	205 (26.2)	198 (25.3)
39.0 – 39.9	833 (11.0)	355 (13.0)	328 (10.1)	84 (10.7)	66 (8.4)
> 39.9	109 (1.4)	47 (1.7)	42 (1.3)	12 (1.5)	8 (1.0)
Respiratory rate (breaths/min)					
Mean, (SD)	NA	23 (7)	22 (7)	NA	NA
< 16	945 (12.0)	200 (7.6)	292 (9.3)	245 (22.6)	208 (20.3)
16 – 21	3421 (43.4)	1114 (42.2)	1309 (41.8)	534 (49.2)	464 (45.3)
22 – 29	2370 (30.1)	848 (32.1)	1053 (33.6)	219 (20.2)	250 (24.4)
> 29	1145 (14.5)	477 (18.1)	478 (15.3)	87 (8.0)	103 (10.0)
Heart rate (beats/min)					
Mean, (SD)	NA	93 (18)	88 (20)	NA	NA
<45	36 (0.4)	7 (0.3)	18 (0.6)	5 (0.3)	6 (0.4)
45 – 59	218 (2.5)	32 (1.2)	104 (3.2)	34 (2.4)	48 (3.5)
60 – 89	4617 (52.4)	1167 (42.6)	1764 (54.1)	814 (56.7)	872 (63.1)
90 – 119	3404 (38.6)	1346 (49.1)	1153 (35.4)	521 (36.3)	384 (27.8)
>119	544 (6.2)	190 (6.9)	221 (6.8)	61 (4.3)	72 (5.2)
Systolic blood pressure (mmHg)					
Mean, (SD)	NA	131 (21)	135 (24)	NA	NA
<80	47 (0.6)	11 (0.4)	25 (0.8)	2 (0.3)	9 (1.1)
80 – 99	349 (4.6)	110 (4.1)	171 (5.3)	24 (3.1)	44 (5.6)
100 – 119	1648 (21.9)	626 (23.1)	679 (20.9)	185 (23.6)	158 (20.0)
120 – 139	2764 (36.7)	1110 (40.9)	1062 (32.7)	335 (42.7)	257 (32.5)
140 – 179	2489 (33.0)	799 (29.5)	1179 (36.3)	224 (28.6)	287 (36.3)
>179	240 (3.2)	56 (2.1)	134 (4.1)	14 (1.8)	36 (4.6)
Diastolic blood pressure (mmHg)					
Mean, (SD)	NA	78 (13)	74 (15)	NA	NA
< 40	27 (0.4)	7 (0.3)	14 (0.4)	2 (0.3)	4 (0.5)
40 – 59	821 (10.9)	201 (7.4)	472 (14.5)	35 (4.5)	113 (14.3)
60 – 89	5399 (71.7)	1980 (73.0)	2271 (69.9)	592 (75.8)	556 (70.6)
90 – 109	1157 (15.4)	485 (17.9)	428 (13.2)	139 (17.8)	105 (13.3)

> 109	125 (1.7)	38 (1.4)	64 (2.0)	13 (1.7)	10 (1.3)
Oxygen saturation (%)					
Median, [IQR]	NA	95 [93 – 97]	95 [92 – 97]	NA	NA
< 60	45 (0.6)	17 (0.6)	9 (0.3)	7 (0.9)	12 (1.6)
60 – 69	38 (0.5)	16 (0.6)	13 (0.4)	2 (0.3)	7 (0.9)
70 – 79	133 (1.8)	45 (1.6)	46 (1.4)	14 (1.8)	28 (3.6)
80 – 89	853 (11.3)	262 (9.6)	366 (11.2)	75 (9.6)	150 (19.5)
90 – 95	3156 (41.8)	1080 (39.4)	1459 (44.7)	291 (37.4)	326 (42.3)
96 – 100	3331 (44.1)	1321 (48.2)	1372 (42.0)	390 (50.1)	248 (32.2)
Laboratory values at admission (%)					
CRP (mg/L)					
Mean, (SD)	NA	109 (96)	107 (86)	NA	NA
< 3	295 (4.0)	62 (2.3)	54 (1.7)	120 (14.6)	59 (7.2)
3 – 29	1518 (20.5)	483 (18.1)	493 (15.9)	308 (37.5)	234 (28.7)
30 – 69	1735 (23.4)	637 (23.9)	749 (24.2)	161 (19.6)	188 (23.1)
70 – 119	1458 (19.7)	539 (20.2)	677 (21.8)	95 (11.6)	147 (18.0)
120 – 179	1151 (15.5)	412 (15.4)	554 (17.9)	84 (10.2)	101 (12.4)
180 – 249	674 (9.1)	271 (10.2)	320 (10.3)	30 (3.7)	53 (6.5)
> 249	575 (7.8)	265 (9.9)	254 (8.2)	23 (2.8)	33 (4.0)
White blood cell count (x 10^9/L)					
Mean, (SD)	NA	7.7 (4.2)	7.9 (4.2)	NA	NA
< 1.0	21 (0.3)	9 (0.3)	9 (0.3)	1 (0.1)	2 (0.2)
1.0 – 3.9	871 (11.8)	308 (11.5)	310 (10.1)	144 (17.5)	109 (13.3)
4.0 – 7.9	3922 (53.1)	1409 (52.7)	1599 (52.1)	483 (58.7)	431 (52.6)
8.0 – 11.9	1804 (24.4)	681 (25.5)	811 (26.4)	142 (17.3)	170 (20.7)
12.0 – 15.9	560 (7.6)	207 (7.7)	257 (8.4)	33 (4.0)	63 (7.7)
16.0 – 19.9	179 (2.4)	61 (2.3)	81 (2.6)	11 (1.3)	26 (3.2)
> 20	28 (0.4)	0 (0.0)	0 (0.0)	9 (1.1)	19 (2.3)
Lymphocyte count (x 10^9/L)					
Mean, (SD)	NA	1.12 (0.81)	0.99 (0.83)	NA	NA
< 0.1	37 (0.6)	4 (0.2)	11 (0.4)	9 (1.4)	13 (1.9)
0.10 – 0.29	215 (3.7)	36 (1.8)	111 (4.5)	18 (2.8)	50 (7.3)
0.30 – 0.49	559 (9.7)	117 (6.0)	327 (13.3)	47 (7.2)	68 (10.0)
0.50 – 0.79	1501 (26.2)	470 (24.0)	704 (28.7)	127 (19.6)	200 (29.4)
0.80 – 1.49	2456 (42.8)	957 (48.9)	957 (39.1)	288 (44.4)	254 (37.3)
1.50 – 2.99	874 (15.2)	341 (17.4)	301 (12.3)	147 (22.7)	85 (12.5)
> 3.0	94 (1.6)	31 (1.6)	39 (1.6)	13 (2.0)	11 (1.6)
Hemoglobin (mmol/L)					
Mean, (SD)	NA	8.3 (1.3)	8.0 (1.3)	NA	NA
< 3.73	16 (0.2)	5 (0.2)	7 (0.2)	0 (0.0)	4 (0.5)
3.73 – 4.90	102 (1.4)	29 (1.1)	30 (1.0)	12 (1.5)	31 (3.8)
4.91 – 6.15	426 (5.9)	119 (4.6)	203 (6.9)	31 (3.8)	73 (8.9)
6.16 – 7.39	1234 (17.2)	350 (13.7)	606 (20.5)	106 (12.9)	172 (21.0)
7.4 – 9.25	4069 (56.8)	1460 (57.0)	1674 (56.5)	487 (59.2)	448 (54.8)
>= 9.25	1314 (18.3)	597 (23.3)	441 (14.9)	186 (22.6)	90 (11.0)
Platelets (x 10^9/L)					
Mean, (SD)	NA	233 (102)	218 (99)	NA	NA
< 10	16 (0.2)	1 (0.0)	6 (0.2)	3 (0.4)	6 (0.7)
10 – 49	55 (0.8)	16 (0.7)	21 (0.8)	8 (1.0)	10 (1.2)
50 – 119	589 (8.7)	140 (5.8)	274 (10.1)	72 (8.8)	103 (12.6)
120 – 449	5886 (87.0)	2164 (89.4)	2333 (85.9)	718 (88.0)	671 (82.3)
450 – 799	217 (3.2)	95 (3.9)	82 (3.0)	15 (1.8)	25 (3.1)
800 – 1199	5 (0.1)	4 (0.2)	1 (0.0)	0 (0.0)	0 (0.0)
Creatinine (μmol/L)	NA	94 (80)	112 (83)	NA	NA

CRP = C-Reactive Protein; IQR = Interquartile Range; SD = Standard Deviation

Table S5: Baseline characteristics stratified by admission to a critical care unit

	Overall	Ward	Critical care
Total	10481	7826	2655
Age, years (%)			
18 – 25	148 (1.4)	131 (1.7)	17 (0.6)
26 – 35	429 (4.1)	378 (4.8)	51 (1.9)
36 – 45	717 (6.8)	560 (7.2)	157 (5.9)
46 – 55	1503 (14.3)	1063 (13.6)	440 (16.6)
56 – 65	2218 (21.2)	1449 (18.5)	769 (29.0)
66 – 75	2346 (22.4)	1552 (19.8)	794 (29.9)
76 – 85	2247 (21.4)	1867 (23.9)	380 (14.3)
>85	873 (8.3)	826 (10.6)	47 (1.8)
Sex, female (%)	4051 (38.7)	3321 (42.4)	730 (27.5)
Ethnicity			
Arab	458 (5.0)	311 (4.5)	147 (6.6)
Asian	518 (5.7)	360 (5.2)	158 (7.1)
Black	278 (3.0)	224 (3.2)	54 (2.4)
Latin-American	25 (0.3)	18 (0.3)	7 (0.3)
White	7606 (83.1)	5799 (83.8)	1807 (80.9)
Other	269 (2.9)	208 (3.0)	61 (2.7)
BMI (kg/m²)			
Underweight (<18.5)	125 (1.8)	107 (2.2)	18 (0.9)
Normal weight (18.5 – 24.9)	2095 (30.1)	1622 (32.6)	473 (23.7)
Overweight (25.0 – 29.9)	2691 (38.6)	1855 (37.3)	836 (41.8)
Obese (30.0 – 34.9)	1372 (19.7)	934 (18.8)	438 (21.9)
Morbidly obese (> 34.9)	685 (9.8)	451 (9.1)	234 (11.7)
Cardiovascular risk factors			
Diabetes	2482 (24.0)	1827 (23.6)	655 (25.2)
Hypertension	4973 (48.4)	3720 (48.4)	1253 (48.5)
Peripheral arterial disease	442 (5.1)	342 (5.3)	100 (4.5)
Cardiac disease			
Any history of cardiac disease	3195 (30.5)	2500 (31.9)	695 (26.2)
Arrhythmia/conduction disorder	1557 (14.9)	1232 (15.8)	325 (12.3)
Atrial fibrillation/flutter	1238 (11.9)	973 (12.5)	265 (10.1)
Coronary artery disease	1589 (15.2)	1209 (15.5)	380 (14.3)
Myocardial infarction	497 (4.8)	379 (4.9)	118 (4.5)
Heart failure	762 (7.4)	605 (7.8)	157 (6.0)
NYHA I/II	182 (1.8)	145 (1.9)	37 (1.4)
NYHA III/IV	129 (1.3)	96 (1.3)	33 (1.3)
Valvular heart disease	402 (3.9)	342 (4.4)	60 (2.3)
Comorbidities			
Chronic kidney disease	1274 (12.3)	1000 (12.9)	274 (10.5)
COPD	994 (9.6)	755 (9.8)	239 (9.1)
Use cardiovascular drugs			
ACE-inhibitors	1848 (18.1)	1401 (18.1)	447 (17.9)
Aldosterone antagonist	390 (3.8)	319 (4.1)	71 (2.8)
Anti-platelet	2003 (19.4)	1555 (20.0)	448 (17.5)
Angiotensin receptor blocker	1340 (13.1)	1007 (13.1)	333 (13.3)
Calcium-blocker	1658 (16.0)	1190 (15.3)	468 (18.3)
Diuretic	2032 (19.7)	1598 (20.6)	434 (17.0)
Insulin	699 (6.7)	518 (6.6)	181 (6.9)
Lipid-lowering	2978 (30.2)	2306 (31.1)	672 (27.5)
Oral anti-diabetic	1258 (12.0)	947 (12.1)	311 (11.7)

ACE = Angiotensin Converting Enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; NYHA = New York Heart Association

Table S6: Complaints, vitals and laboratory values at admission stratified by admission to a critical care unit

	Overall	Ward	Critical care
Total	10481	7826	2655
Admission			
Onset of symptoms to admission, days, median, [IQR]	6 [2 – 9]	6 [2 – 9]	7 [3 – 9]
Complaints at admission			
Anosmia	402 (4.1)	325 (4.6)	77 (2.9)
Cough	5472 (56.4)	4025 (56.8)	1447 (55.4)
Dyspnea	5056 (52.6)	3495 (49.8)	1561 (60.3)
Fatigue	2777 (28.6)	2097 (29.6)	680 (26.0)
Fever	5852 (60.3)	4222 (59.6)	1630 (62.4)
Gastrointestinal symptoms	2055 (21.2)	1532 (21.6)	523 (20.0)
Palpitations	117 (1.2)	86 (1.2)	31 (1.2)
Sore throat	776 (8.0)	609 (8.6)	167 (6.4)
Vitals at admission			
Temperature (°C)			
< 35.1	49 (0.6)	36 (0.6)	13 (0.7)
35.1 – 37.2	2821 (37.4)	2256 (39.6)	565 (30.6)
37.3 – 37.9	1698 (22.5)	1316 (23.1)	382 (20.7)
38.0 – 38.9	2030 (26.9)	1454 (25.5)	576 (31.2)
39.0 – 39.9	833 (11.0)	569 (10.0)	264 (14.3)
> 39.9	109 (1.4)	64 (1.1)	45 (2.4)
Respiratory rate (breaths/min)			
< 16	945 (12.0)	780 (13.1)	165 (8.5)
16 – 21	3421 (43.4)	2826 (47.6)	595 (30.6)
22 – 29	2370 (30.1)	1675 (28.2)	695 (35.7)
> 29	1145 (14.5)	654 (11.0)	491 (25.2)
Heart rate (beats/min)			
< 45	36 (0.4)	27 (0.4)	9 (0.4)
45 – 59	218 (2.5)	170 (2.5)	48 (2.2)
60 – 89	4617 (52.4)	3615 (54.2)	1002 (46.6)
90 – 119	3404 (38.6)	2489 (37.3)	915 (42.5)
> 119	544 (6.2)	366 (5.5)	178 (8.3)
Systolic blood pressure (mmHg)			
< 80	47 (0.6)	35 (0.6)	12 (0.7)
80 – 99	349 (4.6)	238 (4.2)	111 (6.1)
100 – 119	1648 (21.9)	1224 (21.4)	424 (23.2)
120 – 139	2764 (36.7)	2154 (37.7)	610 (33.4)
140 – 179	2489 (33.0)	1889 (33.1)	600 (32.9)
> 179	240 (3.2)	171 (3.0)	69 (3.8)
Diastolic blood pressure (mmHg)			
< 40	27 (0.4)	12 (0.2)	15 (0.8)
40 – 59	821 (10.9)	532 (9.3)	289 (15.9)
60 – 89	5399 (71.7)	4162 (72.9)	1237 (67.9)
90 – 109	1157 (15.4)	898 (15.7)	259 (14.2)
> 109	125 (1.7)	102 (1.8)	23 (1.3)
Oxygen saturation (%)			
< 60	45 (0.6)	13 (0.2)	32 (1.7)
60 – 69	38 (0.5)	13 (0.2)	25 (1.3)
70 – 79	133 (1.8)	49 (0.9)	84 (4.5)
80 – 89	853 (11.3)	453 (8.0)	400 (21.5)
90 – 95	3156 (41.8)	2362 (41.5)	794 (42.6)
96 – 100	3331 (44.1)	2804 (49.2)	527 (28.3)

Laboratory values at admission			
CRP (mg/L)			
< 3	295 (4.0)	274 (4.9)	21 (1.1)
3 – 29	1518 (20.5)	1342 (24.1)	176 (9.6)
30 – 69	1735 (23.4)	1441 (25.9)	294 (16.0)
70 – 119	1458 (19.7)	1094 (19.7)	364 (19.8)
120 – 179	1151 (15.5)	775 (13.9)	376 (20.4)
180 – 249	674 (9.1)	389 (7.0)	285 (15.5)
> 249	575 (7.8)	252 (4.5)	323 (17.6)
White blood cell count (x 10 ⁹ /L)			
< 1.0	21 (0.3)	16 (0.3)	5 (0.3)
1.0 – 3.9	871 (11.8)	705 (12.7)	166 (9.1)
4.0 – 7.9	3922 (53.1)	3089 (55.5)	833 (45.7)
8.0 – 11.9	1804 (24.4)	1290 (23.2)	514 (28.2)
12.0 – 15.9	560 (7.6)	323 (5.8)	237 (13.0)
16.0 – 19.9	179 (2.4)	121 (2.2)	58 (3.2)
> 20	28 (0.4)	18 (0.3)	10 (0.5)
Lymphocyte count (x 10 ⁹ /L)			
< 0.1	37 (0.6)	27 (0.6)	10 (0.8)
0.10 – 0.29	215 (3.7)	146 (3.3)	69 (5.5)
0.30 – 0.49	559 (9.7)	403 (9.0)	156 (12.4)
0.50 – 0.79	1501 (26.2)	1122 (25.1)	379 (30.1)
0.80 – 1.49	2456 (42.8)	1940 (43.3)	516 (41.0)
1.50 – 2.99	874 (15.2)	764 (17.1)	110 (8.7)
> 3.0	94 (1.6)	75 (1.7)	19 (1.5)
Hemoglobin (mmol/L)			
< 3.73	16 (0.2)	14 (0.3)	2 (0.1)
3.73 – 4.90	102 (1.4)	70 (1.3)	32 (1.8)
4.91 – 6.15	426 (5.9)	301 (5.6)	125 (7.1)
6.16 – 7.39	1234 (17.2)	946 (17.5)	288 (16.4)
7.4 – 9.25	4069 (56.8)	3079 (57.0)	990 (56.2)
>= 9.25	1314 (18.3)	990 (18.3)	324 (18.4)
Platelets (x 10 ⁹ /L)			
< 10	16 (0.2)	9 (0.2)	7 (0.4)
10 – 49	55 (0.8)	40 (0.8)	15 (0.9)
50 – 119	589 (8.7)	428 (8.4)	161 (9.5)
120 – 449	5886 (87.0)	4424 (87.2)	1462 (86.4)
450 – 799	217 (3.2)	171 (3.4)	46 (2.7)
800 – 1199	5 (0.1)	3 (0.1)	2 (0.1)

CRP = C-Reactive Protein

Table S7: Baseline characteristics stratified by mortality

	Overall	Discharged alive	Died during admission
Total	10481	8370	2111
Age, years (%)			
18 – 25	148 (1.4)	145 (1.7)	3 (0.1)
26 – 35	429 (4.1)	414 (4.9)	15 (0.7)
36 – 45	717 (6.8)	697 (8.3)	20 (0.9)
46 – 55	1503 (14.3)	1401 (16.7)	102 (4.8)
56 – 65	2218 (21.2)	1955 (23.4)	263 (12.5)
66 – 75	2346 (22.4)	1786 (21.3)	560 (26.5)
76 – 85	2247 (21.4)	1462 (17.5)	785 (37.2)
>85	873 (8.3)	510 (6.1)	363 (17.2)
Sex, female (%)	4051 (38.7)	3369 (40.3)	682 (32.3)
Ethnicity			
Arab	458 (5.0)	388 (5.3)	70 (3.8)
Asian	518 (5.7)	423 (5.8)	95 (5.1)
Black	278 (3.0)	234 (3.2)	44 (2.4)
Latin-American	25 (0.3)	22 (0.3)	3 (0.2)
White	7606 (83.1)	6009 (82.4)	1597 (85.8)
Other	269 (2.9)	216 (3.0)	53 (2.8)
BMI (kg/m²)			
Underweight (<18.5)	125 (1.8)	82 (1.5)	43 (3.1)
Normal weight (18.5 – 24.9)	2095 (30.1)	1671 (30.0)	424 (30.5)
Overweight (25.0 – 29.9)	2691 (38.6)	2159 (38.7)	535 (38.3)
Obese (30.0 – 34.9)	1372 (19.7)	1118 (20.0)	254 (18.3)
Morbidly obese (> 34.9)	685 (9.8)	549 (9.8)	136 (9.8)
Cardiovascular risk factors			
Diabetes	2482 (24.0)	1802 (21.8)	680 (33.0)
Hypertension	4973 (48.4)	3708 (45.1)	1265 (61.9)
Peripheral arterial disease	442 (5.1)	303 (4.3)	139 (8.3)
Cardiac disease			
Any history of cardiac disease	3195 (30.5)	2227 (26.6)	968 (45.9)
Arrhythmia/conduction disorder	1557 (14.9)	1036 (12.4)	521 (24.7)
Atrial fibrillation/flutter	1238 (11.9)	808 (9.7)	430 (20.6)
Coronary artery disease	1589 (15.2)	1108 (13.3)	481 (22.8)
Myocardial infarction	497 (4.8)	351 (4.3)	146 (7.2)
Heart failure	762 (7.4)	475 (5.7)	287 (13.9)
NYHA I/II	182 (1.8)	121 (1.5)	61 (3.1)
NYHA III/IV	129 (1.3)	66 (0.8)	63 (3.2)
Valvular heart disease	402 (3.9)	265 (3.2)	137 (6.6)
Comorbidities			
Chronic kidney disease	1274 (12.3)	821 (9.9)	453 (21.9)
COPD	994 (9.6)	670 (8.1)	324 (15.7)
Use cardiovascular drugs			
ACE-inhibitors	1848 (18.1)	1395 (17.0)	453 (22.4)
Aldosterone antagonist	390 (3.8)	264 (3.2)	126 (6.1)
Anti-platelet	2003 (19.4)	1461 (17.6)	542 (26.4)
Angiotensin receptor blocker	1340 (13.1)	1051 (12.8)	289 (14.3)
Calcium-blocker	1658 (16.0)	1258 (15.2)	400 (19.5)
Diuretic	2032 (19.7)	1411 (17.0)	621 (30.3)
Insulin	699 (6.7)	477 (5.7)	222 (10.6)
Lipid-lowering	2978 (30.2)	2232 (28.2)	746 (38.0)
Oral anti-diabetic	1258 (12.0)	937 (11.2)	321 (15.2)

ACE = Angiotensin Converting Enzyme; BMI = Body Mass Index; COPD = Chronic Obstructive Pulmonary Disease; NYHA = New York Heart Association

Table S8: Complaints, vitals and laboratory values at admission stratified by mortality

	Overall	Discharged alive	Died during admission
Total	10481	8370	2111
Admission			
Onset of symptoms to admission, days, median, [IQR]	6 [2 – 9]	6 [2 – 9]	4 [1 – 7]
Complaints at admission			
Anosmia	402 (4.1)	379 (4.9)	23 (1.2)
Cough	5472 (56.4)	4468 (57.5)	1004 (52.2)
Dyspnea	5056 (52.6)	3917 (50.8)	1139 (59.9)
Fatigue	2777 (28.6)	2243 (28.8)	534 (27.8)
Fever	5852 (60.3)	4727 (60.8)	1125 (58.5)
Gastrointestinal symptoms	2055 (21.2)	1699 (21.8)	356 (18.5)
Palpitations	117 (1.2)	97 (1.2)	20 (1.0)
Sore throat	776 (8.0)	665 (8.6)	111 (5.8)
Vitals at admission			
Temperature (°C)			
< 35.1	49 (0.6)	31 (0.5)	18 (1.1)
35.1 – 37.2	2821 (37.4)	2267 (38.0)	554 (35.2)
37.3 – 37.9	1698 (22.5)	1351 (22.6)	347 (22.1)
38.0 – 38.9	2030 (26.9)	1580 (26.5)	450 (28.6)
39.0 – 39.9	833 (11.0)	655 (11.0)	178 (11.3)
> 39.9	109 (1.4)	84 (1.4)	25 (1.6)
Respiratory rate (breaths/min)			
< 16	945 (12.0)	830 (13.2)	115 (7.1)
16 – 21	3421 (43.4)	2865 (45.7)	556 (34.4)
22 – 29	2370 (30.1)	1813 (28.9)	557 (34.5)
> 29	1145 (14.5)	759 (12.1)	386 (23.9)
Heart rate (beats/min)			
< 45	36 (0.4)	30 (0.4)	6 (0.3)
45 – 59	218 (2.5)	162 (2.3)	56 (3.1)
60 – 89	4617 (52.4)	3742 (53.2)	875 (49.1)
90 – 119	3404 (38.6)	2735 (38.9)	669 (37.6)
> 119	544 (6.2)	369 (5.2)	175 (9.8)
Systolic blood pressure (mmHg)			
< 80	47 (0.6)	27 (0.5)	20 (1.3)
80 – 99	349 (4.6)	254 (4.3)	95 (6.0)
100 – 119	1648 (21.9)	1276 (21.4)	372 (23.6)
120 – 139	2764 (36.7)	2274 (38.1)	490 (31.2)
140 – 179	2489 (33.0)	1955 (32.8)	534 (33.9)
> 179	240 (3.2)	178 (3.0)	62 (3.9)
Diastolic blood pressure (mmHg)			
< 40	27 (0.4)	19 (0.3)	8 (0.5)
40 – 59	821 (10.9)	549 (9.2)	272 (17.3)
60 – 89	5399 (71.7)	4317 (72.5)	1082 (68.9)
90 – 109	1157 (15.4)	985 (16.5)	172 (10.9)
> 109	125 (1.7)	88 (1.5)	37 (2.4)
Oxygen saturation (%)			
< 60	45 (0.6)	22 (0.4)	23 (1.5)
60 – 69	38 (0.5)	16 (0.3)	22 (1.4)
70 – 79	133 (1.8)	63 (1.1)	70 (4.4)
80 – 89	853 (11.3)	556 (9.3)	297 (18.8)
90 – 95	3156 (41.8)	2507 (42.0)	649 (41.0)
96 – 100	3331 (44.1)	2808 (47.0)	523 (33.0)
Laboratory values at admission			
CRP (mg/L)			

< 3	295 (4.0)	270 (4.6)	25 (1.6)
3 – 29	1518 (20.5)	1355 (23.0)	163 (10.7)
30 – 69	1735 (23.4)	1434 (24.4)	301 (19.7)
70 – 119	1458 (19.7)	1148 (19.5)	310 (20.3)
120 – 179	1151 (15.5)	834 (14.2)	317 (20.8)
180 – 249	674 (9.1)	463 (7.9)	211 (13.8)
> 249	575 (7.8)	376 (6.4)	199 (13.0)
White blood cell count (x 10 ⁹ /L)			
< 1.0	21 (0.3)	16 (0.3)	5 (0.3)
1.0 – 3.9	871 (11.8)	723 (12.3)	148 (9.7)
4.0 – 7.9	3922 (53.1)	3199 (54.5)	723 (47.6)
8.0 – 11.9	1804 (24.4)	1411 (24.1)	393 (25.9)
12.0 – 15.9	560 (7.6)	387 (6.6)	173 (11.4)
16.0 – 19.9	179 (2.4)	113 (1.9)	66 (4.3)
> 20	28 (0.4)	16 (0.3)	12 (0.8)
Lymphocyte count (x 10 ⁹ /L)			
< 0.1	37 (0.6)	22 (0.5)	15 (1.2)
0.10 – 0.29	215 (3.7)	127 (2.8)	88 (7.2)
0.30 – 0.49	559 (9.7)	384 (8.5)	175 (14.3)
0.50 – 0.79	1501 (26.2)	1128 (25.0)	373 (30.4)
0.80 – 1.49	2456 (42.8)	2030 (45.0)	426 (34.7)
1.50 – 2.99	874 (15.2)	747 (16.6)	127 (10.3)
> 3.0	94 (1.6)	70 (1.6)	24 (2.0)
Hemoglobin (mmol/L)			
< 3.73	16 (0.2)	9 (0.2)	7 (0.5)
3.73 – 4.90	102 (1.4)	77 (1.4)	25 (1.7)
4.91 – 6.15	426 (5.9)	277 (4.9)	149 (10.0)
6.16 – 7.39	1234 (17.2)	919 (16.2)	315 (21.2)
7.4 – 9.25	4069 (56.8)	3309 (58.3)	760 (51.2)
>= 9.25	1314 (18.3)	1087 (19.1)	227 (15.3)
Platelets (x 10 ⁹ /L)			
< 10	16 (0.2)	11 (0.2)	5 (0.4)
10 – 49	55 (0.8)	38 (0.7)	17 (1.2)
50 – 119	589 (8.7)	409 (7.6)	180 (13.0)
120 – 449	5886 (87.0)	4745 (88.1)	1141 (82.7)
450 – 799	217 (3.2)	180 (3.3)	37 (2.7)
800 – 1199	5 (0.1)	5 (0.1)	0 (0.0)

CRP = C-Reactive Protein

Table S9: Outcome at discharge stratified by data source and age

	Overall	CAPACITY-COVID		LEOSS	
		≤65 years	>65 years	≤65 years	>65 years
Total	10481	3081	3699	1934	1767
Admission					
Duration of hospitalization, days, median [IQR]	9 [5 – 19]	8 [4 – 18]	9 [5 – 18]	8 [5 – 15]	14 [7 – 23]
Admission to a critical care unit	2655 (25.3)	947 (30.7)	730 (19.7)	487 (25.2)	491 (27.8)
Duration of stay critical care unit, days, median [IQR]	13 [6 – 24]	13 [7 – 23]	13 [6 – 25]	14 [6 – 24]	11 [4 – 24]
Treatment					
Invasive ventilation	1996 (19.1)	788 (25.6)	620 (16.8)	290 (15.0)	298 (16.9)
Non-invasive ventilation	1189 (11.4)	503 (16.4)	386 (10.5)	148 (7.7)	152 (8.6)
ECMO	190 (1.8)	64 (2.1)	15 (0.4)	84 (4.4)	27 (1.5)
Complications					
Cardiac					
Myocarditis	28 (0.3)	9 (0.3)	12 (0.3)	5 (0.3)	2 (0.1)
Myocardial infarction	60 (0.6)	10 (0.4)	28 (0.8)	5 (0.3)	17 (1.0)
Heart failure de novo	115 (1.2)	20 (0.7)	71 (2.1)	6 (0.3)	18 (1.0)
Endocarditis	NA	2 (0.1)	5 (0.1)	NA	NA
Pericarditis	NA	10 (0.4)	2 (0.1)	NA	NA
Ventricular arrhythmia	NA	12 (0.4)	29 (0.8)	NA	NA
Thromboembolic					
Pulmonary embolism	420 (4.2)	187 (6.7)	170 (5.0)	33 (1.7)	30 (1.7)
Stroke	62 (0.6)	15 (0.5)	29 (0.8)	4 (0.2)	14 (0.8)
Venous thrombosis	89 (0.9)	21 (0.7)	13 (0.4)	27 (1.4)	28 (1.6)
Outcome					
Deceased	2111 (20.1)	287 (9.3)	1213 (32.8)	116 (6.0)	495 (28.0)

ECMO = Extracorporeal Membrane Oxygenation; IQR = Interquartile Range

Table S10: Outcome at discharge stratified by admission to a critical care unit

	Overall	Ward	Critical care
Total	10481	7826	2655
Admission			
Duration of hospitalization, days, median [IQR]	9 [5 – 19]	7 [4 – 13]	21 [13 – 35]
Treatment			
Invasive ventilation	1996 (19.1)	0 (0.0)	1996 (75.5)
Non-invasive ventilation	1189 (11.4)	21 (0.3)	1168 (44.6)
ECMO	190 (1.8)	0 (0.0)	190 (7.3)
Complications			
Cardiac			
Myocarditis	28 (0.3)	11 (0.2)	17 (0.7)
Myocardial infarction	60 (0.6)	21 (0.3)	39 (1.5)
Heart failure de novo	115 (1.2)	75 (1.0)	40 (1.5)
Thromboembolic			
Pulmonary embolism	420 (4.2)	90 (1.2)	330 (12.6)
Stroke	62 (0.6)	29 (0.4)	33 (1.3)
Venous thrombosis	89 (0.9)	19 (0.3)	70 (2.7)
Outcome			
Deceased	2111 (20.1)	1280 (16.4)	831 (31.3)

ECMO = Extracorporeal Membrane Oxygenation; IQR = Interquartile Range

Table S11: Outcome at discharge stratified by mortality

	Overall	Discharged alive	Died during admission
Total	10481	8370	2111
Admission			
Duration of hospitalization, days, median [IQR]	9 [5 – 19]	9 [5 – 19]	10 [5 – 19]
Admission to a critical care unit	2655 (25.3)	1824 (21.8)	831 (39.4)
Duration of stay critical care unit, days, median [IQR]	13 [6 – 24]	14 [6 – 26]	12 [6 – 21]
Treatment			
Invasive ventilation	1996 (19.1)	1298 (15.5)	698 (33.1)
Non-invasive ventilation	1189 (11.4)	888 (10.6)	301 (14.3)
ECMO	190 (1.8)	99 (1.2)	91 (4.3)
Complications			
Cardiac			
Myocarditis	28 (0.3)	16 (0.2)	12 (0.6)
Myocardial infarction	60 (0.6)	26 (0.3)	34 (1.7)
Heart failure de novo	115 (1.2)	58 (0.7)	57 (2.9)
Thromboembolic			
Pulmonary embolism	420 (4.2)	301 (3.8)	119 (6.1)
Stroke	62 (0.6)	37 (0.5)	25 (1.3)
Venous thrombosis	89 (0.9)	59 (0.7)	30 (1.5)

ECMO = Extracorporeal Membrane Oxygenation; IQR = Interquartile Range

Table S12: Subgroup analyses

	p-value interaction	RR [95% CI]	p-value subgroup
Multivariable adjusted*			
Age	0.03		
Age ≤65 years		1.24 [0.98 – 1.57]	0.08
Age >65 years		1.04 [0.95 – 1.12]	0.40
Sex	0.81		
Female		1.04 [0.90 – 1.21]	0.58
Male		1.08 [0.98 – 1.19]	0.11
BMI (kg/m²)	0.38		
<30		1.07 [0.97 – 1.18]	0.18
≥30		1.02 [0.85 – 1.22]	0.81
Diabetes	0.21		
No		1.08 [0.98 – 1.19]	0.13
Yes		1.02 [0.90 – 1.17]	0.72
Hypertension	0.07		
No		1.16 [1.01 – 1.33]	0.03
Yes		1.01 [0.92 – 1.11]	0.81
Chronic kidney disease	0.23		
No		1.06 [0.97 – 1.16]	0.20
Yes		1.04 [0.89 – 1.21]	0.65
COPD	0.96		
No		1.04 [0.96 – 1.14]	0.33
Yes		1.13 [0.94 – 1.36]	0.18

* Multivariable models adjusted are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Germany/Switzerland, Middle – East, Netherlands/Belgium, Russia, Southern – Europe United Kingdom).

Table S13: Sensitivity analyses

	Total cohort		Cohort with exclusion of patients included from centers with selective inclusion	
	RR [95% CI]	p-value	RR [95% CI]	p-value
Crude				
Any cardiac history	1.93 [1.79 – 2.08]	<0.0001	1.97 [1.82 – 2.13]	<0.0001
Arrhythmia/conduction disorder	1.87 [1.72 – 2.03]	<0.0001	1.94 [1.78 – 2.12]	<0.0001
Atrial fibrillation	1.92 [1.76 – 2.09]	<0.0001	2.00 [1.82 – 2.19]	<0.0001
Coronary artery disease	1.65 [1.51 – 1.79]	<0.0001	1.66 [1.51 – 1.82]	<0.0001
Myocardial infarction	1.52 [1.32 – 1.74]	<0.0001	1.54 [1.32 – 1.78]	<0.0001
Heart failure	2.01 [1.82 – 2.23]	<0.0001	2.08 [1.87 – 2.31]	<0.0001
NYHA I/II	1.65 [1.38 – 1.97]	<0.0001	1.67 [1.38 – 2.02]	<0.0001
NYHA III/IV	2.47 [2.15 – 2.85]	<0.0001	2.54 [2.19 – 2.94]	<0.0001
Valvular disease	1.76 [1.53 – 2.03]	<0.0001	1.79 [1.53 – 2.10]	<0.0001
Age and sex adjusted				
Any cardiac history	1.12 [1.03 – 1.21]	0.01	1.12 [1.03 – 1.22]	0.01
Arrhythmia/conduction disorder	1.12 [1.03 – 1.21]	0.01	1.13 [1.03 – 1.23]	0.01
Atrial fibrillation	1.15 [1.05 – 1.25]	<0.001	1.17 [1.07 – 1.28]	<0.001
Coronary artery disease	1.08 [0.99 – 1.18]	0.08	1.06 [0.96 – 1.16]	0.24
Myocardial infarction	1.04 [0.91 – 1.19]	0.60	1.02 [0.88 – 1.19]	0.76
Heart failure	1.28 [1.16 – 1.42]	<0.001	1.29 [1.16 – 1.44]	<0.001
NYHA I/II	1.05 [0.88 – 1.25]	0.58	1.04 [0.86 – 1.25]	0.67
NYHA III/IV	1.56 [1.35 – 1.80]	<0.001	1.56 [1.34 – 1.80]	<0.001
Valvular disease	1.14 [0.99 – 1.31]	0.07	1.14 [0.97 – 1.33]	0.11
Multivariable adjusted*				
Any cardiac disease	1.06 [0.98 – 1.15]	0.13	1.08 [0.99 – 1.17]	0.08
Arrhythmia/conduction disorder	1.09 [1.00 – 1.19]	0.06	1.10 [1.01 – 1.21]	0.04
Atrial fibrillation	1.14 [1.04 – 1.24]	0.01	1.16 [1.05 – 1.28]	<0.001
Coronary artery disease	1.05 [0.96 – 1.14]	0.33	1.03 [0.94 – 1.14]	0.49
Myocardial infarction	1.02 [0.89 – 1.17]	0.74	1.02 [0.88 – 1.18]	0.81
Heart failure	1.14 [1.02 – 1.27]	0.02	1.16 [1.04 – 1.31]	0.01
NYHA I/II	0.98 [0.83 – 1.17]	0.86	1.00 [0.82 – 1.20]	0.97
NYHA III/IV	1.43 [1.22 – 1.68]	<0.001	1.47 [1.24 – 1.73]	<0.001
Valvular disease	1.07 [0.93 – 1.24]	0.33	1.06 [0.91 – 1.25]	0.46

* Multivariable models adjusted are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Germany/Switzerland, Middle – East, Netherlands/Belgium, Russia, Southern – Europe United Kingdom). The models testing the association between a specific heart disease subtype and in-hospital mortality are also adjusted for the presence of other cardiac comorbidities (i.e. the model testing the association between heart failure and in-hospital mortality is adjusted for arrhythmia/conduction disorder, coronary artery disease and valvular disease).

Table S14 Associations across data sources

	CAPACITY-COVID		LEOSS		Total	
	RR [95% CI]	p-value	RR [95% CI]	p-value	RR [95% CI]	p-value
Crude						
Any cardiac history	1.64 [1.50 – 1.79]	<0.0001	2.76 [2.40 – 3.18]	<0.0001	1.93 [1.79 – 2.08]	<0.0001
Arrhythmia/conduction disorder	1.65 [1.49 – 1.82]	<0.0001	2.50 [2.16 – 2.89]	<0.0001	1.87 [1.72 – 2.03]	<0.0001
Atrial fibrillation	1.70 [1.52 – 1.90]	<0.0001	2.55 [2.20 – 2.96]	<0.0001	1.92 [1.76 – 2.09]	<0.0001
Coronary artery disease	1.46 [1.31 – 1.62]	<0.0001	2.15 [1.85 – 2.50]	<0.0001	1.65 [1.51 – 1.79]	<0.0001
Myocardial infarction	1.33 [1.10 – 1.61]	<0.0001	1.98 [1.61 – 2.43]	<0.0001	1.52 [1.32 – 1.74]	<0.0001
Heart failure	1.77 [1.55 – 2.02]	<0.0001	2.69 [2.29 – 3.16]	<0.0001	2.01 [1.82 – 2.23]	<0.0001
NYHA I/II	1.56 [1.25 – 1.95]	<0.0001	1.98 [1.44 – 2.72]	<0.0001	1.65 [1.38 – 1.97]	<0.0001
NYHA III/IV	2.28 [1.80 – 2.90]	<0.0001	3.16 [2.56 – 3.90]	<0.0001	2.47 [2.15 – 2.85]	<0.0001
Valvular disease	1.63 [1.39 – 1.91]	<0.0001	2.03 [1.50 – 2.75]	<0.0001	1.76 [1.53 – 2.03]	<0.0001
Age and sex adjusted						
Any cardiac history	1.02 [0.93 – 1.12]	0.68	1.37 [1.18 – 1.59]	<0.001	1.12 [1.03 – 1.21]	0.01
Arrhythmia/conduction disorder	1.06 [0.96 – 1.17]	0.26	1.27 [1.10 – 1.48]	<0.001	1.12 [1.03 – 1.21]	0.01
Atrial fibrillation	1.09 [0.98 – 1.22]	0.12	1.33 [1.14 – 1.54]	<0.001	1.15 [1.05 – 1.25]	<0.001
Coronary artery disease	1.03 [0.93 – 1.15]	0.54	1.20 [1.03 – 1.39]	0.02	1.08 [0.99 – 1.18]	0.08
Myocardial infarction	0.98 [0.82 – 1.18]	0.85	1.16 [0.94 – 1.42]	0.16	1.04 [0.91 – 1.19]	0.60
Heart failure	1.19 [1.05 – 1.36]	0.01	1.49 [1.26 – 1.75]	<0.001	1.28 [1.16 – 1.42]	<0.001
NYHA I/II	1.05 [0.84 – 1.30]	0.69	1.10 [0.80 – 1.51]	0.56	1.05 [0.88 – 1.25]	0.58
NYHA III/IV	1.52 [1.21 – 1.91]	<0.001	1.74 [1.39 – 2.17]	<0.001	1.56 [1.35 – 1.80]	<0.001
Valvular disease	1.10 [0.94 – 1.29]	0.22	1.15 [0.85 – 1.54]	0.36	1.14 [0.99 – 1.31]	0.07
Multivariable adjusted*						
Any cardiac disease	0.99 [0.91 – 1.09]	0.91	1.24 [1.06 – 1.45]	0.01	1.06 [0.98 – 1.15]	0.13
Arrhythmia/conduction disorder	1.06 [0.95 – 1.18]	0.28	1.12 [0.96 – 1.31]	0.15	1.09 [1.00 – 1.19]	0.06
Atrial fibrillation	1.09 [0.98 – 1.22]	0.12	1.18 [1.01 – 1.38]	0.04	1.14 [1.04 – 1.24]	0.01
Coronary artery disease	1.02 [0.92 – 1.14]	0.67	1.05 [0.90 – 1.23]	0.54	1.05 [0.96 – 1.14]	0.33
Myocardial infarction	0.97 [0.81 – 1.17]	0.77	1.03 [0.83 – 1.26]	0.81	1.02 [0.89 – 1.17]	0.74
Heart failure	1.04 [0.90 – 1.20]	0.59	1.25 [1.04 – 1.50]	0.02	1.14 [1.02 – 1.27]	0.02
NYHA I/II	0.98 [0.78 – 1.22]	0.84	0.97 [0.70 – 1.33]	0.84	0.98 [0.83 – 1.17]	0.86
NYHA III/IV	1.31 [1.03 – 1.67]	0.03	1.43 [1.12 – 1.83]	<0.001	1.43 [1.22 – 1.68]	<0.001
Valvular disease	1.10 [0.94 – 1.29]	0.23	1.01 [0.75 – 1.36]	0.94	1.07 [0.93 – 1.24]	0.33

* Multivariable models adjusted are adjusted for the following covariates: age, sex, BMI, hypertension, CKD, COPD, diabetes and region of inclusion (Germany/Switzerland, Middle – East, Netherlands/Belgium, Russia, Southern – Europe United Kingdom). The models testing the association between a specific heart disease subtype and in-hospital mortality are also adjusted for the presence of other cardiac comorbidities (i.e. the model testing the association between heart failure and in-hospital mortality is adjusted for arrhythmia/conduction disorder, coronary artery disease and valvular disease).